These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21077637)

  • 21. Drug and drug candidate building block analysis.
    Wang J; Hou T
    J Chem Inf Model; 2010 Jan; 50(1):55-67. PubMed ID: 20020714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging chemical patterns: a new methodology for molecular classification and compound selection.
    Auer J; Bajorath J
    J Chem Inf Model; 2006; 46(6):2502-14. PubMed ID: 17125191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Classification of compounds with distinct or overlapping multi-target activities and diverse molecular mechanisms using emerging chemical patterns.
    Namasivayam V; Hu Y; Balfer J; Bajorath J
    J Chem Inf Model; 2013 Jun; 53(6):1272-81. PubMed ID: 23692475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Escape from flatland: increasing saturation as an approach to improving clinical success.
    Lovering F; Bikker J; Humblet C
    J Med Chem; 2009 Nov; 52(21):6752-6. PubMed ID: 19827778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similarity metrics for ligands reflecting the similarity of the target proteins.
    Schuffenhauer A; Floersheim P; Acklin P; Jacoby E
    J Chem Inf Comput Sci; 2003; 43(2):391-405. PubMed ID: 12653501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drugs in other drugs: a new look at drugs as fragments.
    Siegel MG; Vieth M
    Drug Discov Today; 2007 Jan; 12(1-2):71-9. PubMed ID: 17198975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complex molecules: do they add value?
    Selzer P; Roth HJ; Ertl P; Schuffenhauer A
    Curr Opin Chem Biol; 2005 Jun; 9(3):310-6. PubMed ID: 15939334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?
    Ajay A; Walters WP; Murcko MA
    J Med Chem; 1998 Aug; 41(18):3314-24. PubMed ID: 9719583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Many drugs contain unique scaffolds with varying structural relationships to scaffolds of currently available bioactive compounds.
    Hu Y; Bajorath J
    Eur J Med Chem; 2014 Apr; 76():427-34. PubMed ID: 24602788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Further development of reduced graphs for identifying bioactive compounds.
    Barker EJ; Gardiner EJ; Gillet VJ; Kitts P; Morris J
    J Chem Inf Comput Sci; 2003; 43(2):346-56. PubMed ID: 12653496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clustering and rule-based classifications of chemical structures evaluated in the biological activity space.
    Schuffenhauer A; Brown N; Ertl P; Jenkins JL; Selzer P; Hamon J
    J Chem Inf Model; 2007; 47(2):325-36. PubMed ID: 17286395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drugs and nondrugs: an effective discrimination with topological methods and artificial neural networks.
    Murcia-Soler M; Pérez-Giménez F; García-March FJ; Salabert-Salvador MT; Díaz-Villanueva W; Castro-Bleda MJ
    J Chem Inf Comput Sci; 2003; 43(5):1688-702. PubMed ID: 14502504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A neural network based classification scheme for cytotoxicity predictions:Validation on 30,000 compounds.
    Molnár L; Keseru GM; Papp A; Lorincz Z; Ambrus G; Darvas F
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1037-9. PubMed ID: 16288868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Investigation of the Relationship Between Molecular Topology and CYP3A4 Inhibition for Drug-like Compounds.
    Oka R; Engkvist O; Chen H
    Mol Inform; 2012 Oct; 31(10):719-23. PubMed ID: 27476454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination and mapping of activity-specific descriptor value ranges for the identification of active compounds.
    Eckert H; Bajorath J
    J Med Chem; 2006 Apr; 49(7):2284-93. PubMed ID: 16570925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment.
    Tannergren C; Bergendal A; Lennernäs H; Abrahamsson B
    Mol Pharm; 2009; 6(1):60-73. PubMed ID: 19183105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The scaffold tree: an efficient navigation in the scaffold universe.
    Ertl P; Schuffenhauer A; Renner S
    Methods Mol Biol; 2011; 672():245-60. PubMed ID: 20838972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Considering the impact drug-like properties have on the chance of success.
    Yusof I; Segall MD
    Drug Discov Today; 2013 Jul; 18(13-14):659-66. PubMed ID: 23458995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do biologically relevant compounds have more chance to be drugs?
    Kong DX; Ren W; Lü W; Zhang HY
    J Chem Inf Model; 2009 Oct; 49(10):2376-81. PubMed ID: 19852515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.